HTGC Hercules Capital, Inc.

Hercules Capital has delivered a strong multi year share price run, yet the real question for investors is whether that market performance lines up with the returns it earns on its capital. With the stock now trading around recent levels, the issue is how much of Hercules Capital's capital efficiency is already reflected in the current price. Over the past 5 years, Hercules Capital has returned 78.8%. This puts the spotlight on whether the underlying returns on its investment portfolio and...

Hercules Capital trades at $16.95 and has moved in lockstep with the market. Its shares have returned 19.4% over the last six months while the S&P 500 has gained 22.1%.

Hercules Capital (HTGC) has a fresh governance catalyst. The business appointed Alfred B. Fichera as an independent director and Audit Committee member on 17 September 2026, bringing extensive audit and asset management experience. Hercules Capital’s share price has softened in the short term, with the 30-day share price return down 3.26% and the year-to-date share price return down 10.34%. In contrast, the 1-year total shareholder return is slightly positive at 0.58% and the 5-year total...

The yield you choose determines whether you need $900,000 or over $3 million to hit the same income target, and picking the wrong tier can leave your purchasing power shrinking every year even while the checks keep arriving.

Based on the average brokerage recommendation (ABR), Hercules Capital (HTGC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Hercules Capital (HTGC) closed the most recent trading day at $16.8, moving 1% from the previous trading session.

Hercules Capital (HTGC) closed at $16.97 in the latest trading session, marking a -1.45% move from the prior day.

The yield you chase determines not just how much capital you need, but whether your income quietly erodes over time or quietly grows. The right answer is less obvious than most retirees assume.

Looking back on specialty finance stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Hercules Capital (NYSE:HTGC) and its peers.

Hercules Capital (HTGC) closed at $17.76 in the latest trading session, marking a +1.08% move from the prior day.

The capital required to replace a professional salary with investment income swings by more than $2 million depending on one decision, and most investors default to the wrong tier without realizing it.

Retirees chasing cash flow face a brutal tradeoff between yield and safety, but a carefully chosen mix of net-lease REITs and a venture lender can tip that balance in surprising ways.

Hercules Capital has delivered a powerful 87.8% total return over the past 5 years, yet its current US$17.64 share price raises a sharper question for you as an investor. Are those past gains and the business it has built enough to justify today's valuation when you focus squarely on the returns it earns on its capital? The 87.8% return over 5 years puts real weight on whether Hercules Capital's underlying return on its own capital can support the price level the market is now...

Hercules Capital (HTGC) concluded the recent trading session at $17.39, signifying a -1.25% move from its prior day's close.

The average brokerage recommendation (ABR) for Hercules Capital (HTGC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Three tickers, three wildly different capital requirements, and one retiree pulling a five-figure monthly income without touching principal. Which one demands nearly four times the nest egg of the others, and what does that tradeoff actually cost you over a decade?

Most BDC investors hand thousands of dollars to the IRS every single year without realizing there is one account type that legally keeps all of it. The difference comes down to where you hold these high-yielding positions, and the math is hard to unsee.

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

CION's Q2 results benefit from lower non-accruals, lifting shares 16.9%. However, lower investment income and higher expenses weigh on results.

MAIN's Q2 NII misses estimates as higher expenses offset gains from increased investment income and portfolio activity.

While income investors keep circling the same REITs and MLPs, three finance-sector names with yields that dwarf typical dividend stalwarts have been hiding in plain sight, and the safety case for each one is stronger than the headline numbers suggest.

Hercules Capital stock has delivered a 63.8% gain over the past five years, yet several valuation checks suggest the current share price of US$16.42 may still sit below what the business is worth. Both the intrinsic value estimate based on the Excess Returns model and the market multiple checks currently point in the same direction, which puts extra focus on whether the recent share price weakness this year has already accounted for key risks. Over five years Hercules Capital has returned...

Hercules Capital, Inc. reported strong past results for the second quarter and first half of 2026, with Q2 revenue rising to US$149.11 million and net income to US$130.18 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. Alongside these earnings, Hercules Capital increased its regular quarterly dividend to US$0.47 per share, declared a US$0.07 supplemental distribution, and recently completed a US$321.27 million fixed‑income...

Why Hercules Capital’s latest quarter matters for shareholders Hercules Capital (HTGC) just reported Q2 2026 results that featured record originations, investment income and net investment income, alongside higher revenue and net income and early loan repayments that ran ahead of guidance. Management also highlighted steady portfolio credit quality, strong liquidity and ongoing contributions from the company’s private credit business. Taken together, these factors framed Q2 as an important...

Hercules Capital's shares up 3% after Q2 earnings meet estimates and record total investment income climbs 8.5%, while higher expenses weigh on performance.

Hercules Capital (NYSE:HTGC) reported record second-quarter investment income and net investment income, supported by strong originations, elevated early loan repayments and stable portfolio credit performance. Chief Executive Officer and Chief Investment Officer Scott Bluestein said the business c

Hercules Capital Inc (HTGC) posts record Q2 2026 investment income and NAV growth, navigating competitive pressures with disciplined underwriting and robust portfolio health.

Record originations of $2.74 billion drove net investment income to $92.9 million.

Hercules Capital (HTGC) delivered earnings and revenue surprises of 0.00% and +0.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Specialty finance company Hercules Capital (NYSE:HTGC) will be announcing earnings results this Thursday after market close. Here’s what to look for.

In the latest trading session, Hercules Capital (HTGC) closed at $15.93, marking a -1.24% move from the previous day.

The latest trading day saw Hercules Capital (HTGC) settling at $16.37, representing a +1.61% change from its previous close.

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now. On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that the company’s Force platform has the potential to improve drug delivery in neuromuscular and CNS diseases […]

PhenixFIN (PFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.